Ann: Kazia marks DIPG Awareness Day, page-5

Kazia supplied paxalisib to Matt Dun for compassionate research relating to his daughter's DIPG condition.
IMO that is why Kazia has not commented on paxalisib's combination data results, until they are published in a few weeks.

Hence, the commencement of the PNOC clinical study, a multi-drug phase II study in DIPG and diffuse midline gliomas, has been initiated at the University of California, San Francisco, with the first patient successfully enrolled to the study in November 2021.

Regards.